Changes of Apolipoprotein M Gene Expression During the Cell Differentiation and Apoptosis Induced by Simvastatin in Combination with All-Trans Retinoic Acid in Human Promyelocytic Leukemia Cell Line NB4

  • Weiying Gu
  • Lili Xiang
  • Tingxiu Jiang
  • Guanghua Luo
  • Jiang Wei
  • Jiannong Cen
  • Zixing Chen
  • Guoqiang Qiu
  • Mei Zeng
  • Xiaoying ZhangEmail author
Original Article


We examined the effect of simvastatin (SV) alone and in combination with all-trans retinoic acid (ATRA) on proliferation, differentiation, apoptosis and apolipoprotein M (apoM) expression in the human promyelocytic leukemia cell line NB4. The NB4 cells were incubated with 10 μM Simvastatin (10SV) and 0.5 μM ATRA alone or in combination, taking NB4 cells without any treatment as normal controls. The cells of different groups were collected at 24, 48 and 72 h post-incubation for further detection. Their morphological changes were observed after Wright stain. MTT method was used to assay the growth inhibition rate and flow cytometry to detect CD11b expression level and the early stage apoptosis ratio. Real-time quantitative reverse transcriptase-polymerase chain reaction was used to detect the apoM gene expression levels. As expected 0.5 μM ATRA did not affect proliferation or apoptosis, strongly induced differentiation and decreased apoM expression. 10SV inhibited proliferation, increased apoptosis, induced differentiation and increased apoM expression in a time-dependent manner. The addition of ATRA to SV did not increase the effect of SV on proliferation and apoptosis, but increased the effect of SV on differentiation. And completely abrogated the effect of SV on apoM expression. Together these results show that SV has anti-leukemic properties by itself and that combined therapy may have a place in the current anti-leukemic arsenal.


Simvastatin NB4 cell All-trans retinoic acid Cell apoptosis Apolipoprotein M gene 


  1. 1.
    Chan KK, Oza AM, Siu LL (2003) The statins as anticancer agents. Clin Cancer Res 9:10–19PubMedGoogle Scholar
  2. 2.
    Brower V (2003) Of cancer and cholesterol: studies elucidate anticancer mechanisms of statins. J Natl Cancer Inst 95:844–846CrossRefPubMedGoogle Scholar
  3. 3.
    Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM (2005) Statins and cancer prevention. Nat Rev Cancer 5:930–942CrossRefPubMedGoogle Scholar
  4. 4.
    Sassano A, Platanias LC (2008) Statins in tumor suppression. Cancer Lett 260:11–19CrossRefPubMedGoogle Scholar
  5. 5.
    Hindler K, Cleeland CS, Rivera E, Collard CD (2006) The role of statins in cancer therapy. Oncologist 11:306–315CrossRefPubMedGoogle Scholar
  6. 6.
    Tomiyama N, Matzno S, Kitada C, Nishiguchi E, Okamura N, Matsuyama K (2008) The possibility of simvastatin as a chemotherapeutic agent for all-trans retinoic acid-resistant promyelocytic leukemia. Biol Pharm Bull 31:369–374CrossRefPubMedGoogle Scholar
  7. 7.
    Sassano A, Katsoulidis E, Antico G, Katsoulidis E, Antico G, Altman JK, Redig AJ, Minucci S, Tallman MS, Platanias LC (2007) Suppressive effects of statins on acute promyelocytic leukemia cells. Cancer Res 67:4524–4532CrossRefPubMedGoogle Scholar
  8. 8.
    Xu N, Dahlback B (1999) A novel human apolipoprotein (apoM). J Biol Chem 274:31286–31290CrossRefPubMedGoogle Scholar
  9. 9.
    Zhang XY, Dong X, Zheng L, Luo GH, Liu YH, Ekstrom U, Nilsson-Ehle P, Ye Q, Xu N (2003) Specific tissue expression and cellular localization of human apolipoprotein M as determined by in situ hybridization. Acta Histochem 105:67–72CrossRefPubMedGoogle Scholar
  10. 10.
    Luo G, Zhang X, Mu Q, Chen L, Zheng L, Wei J, Berggren-Soderlund M, Nilsson-Ehle P, Xu N (2010) Expression and localization of apolipoprotein M in human colorectal tissues. Lipids Health Dis 9:102PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Hatake K, Uwai M, Ohtsuki T, Tomizuka H, Izumi T, Yoshida M, Miura Y (1997) Rare but important adverse effects of all-trans retinoic acid in acute promyelocytic leukemia and their management. Int J Hematol 66:13–19CrossRefPubMedGoogle Scholar
  12. 12.
    Gu W, Hu S, He B, Qiu G, Ma J, Chen Z (2009) Metabolites of acute promyelocytic leukemia cells participate in contributing to hypertriglyceridemia induced by all-trans retinoic acid. Leuk Res 33:592–594CrossRefPubMedGoogle Scholar
  13. 13.
    Wang ZY, Chen Z (2008) Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111:2505–2515CrossRefPubMedGoogle Scholar
  14. 14.
    van der Weide K, de Jonge-Peeters SD, Kuipers F, Vries EG, Vellenga E (2009) Combining simvastatin with the farnesyltransferase inhibitor tipifarnib results in an enhanced cytotoxic effect in a subset of primary CD34 + acute myeloid leukemia samples. Clin Cancer Res 15:3076–3083CrossRefPubMedGoogle Scholar
  15. 15.
    Ho YK, Smith RG, Brown MS, Goldstein JL (1978) Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells. Blood 52:1099–1114PubMedGoogle Scholar
  16. 16.
    Firestone RA (1994) Low-density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells. Bioconjug Chem 5:105–113CrossRefPubMedGoogle Scholar
  17. 17.
    Vitols S, Norgren S, Juliusson G, Tatidis L, Luthman H (1994) Multilevel regulation of low-density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in normal and leukemic cells. Blood 84:2689–2698PubMedGoogle Scholar
  18. 18.
    Li HY, Appelbaum FR, Willman CL, Zager RA, Banker DE (2003) Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood 101:3628–3634CrossRefPubMedGoogle Scholar
  19. 19.
    Banker DE, Mayer SJ, Li HY, Willman CL, Appelbaum FR, Zager RA (2004) Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells. Blood 104:1816–1824CrossRefPubMedGoogle Scholar
  20. 20.
    Christoffersen C, Obinata H, Kumaraswamy SB, Galvani S, Ahnstrom J, Sevvana M, Egerer-Sieber C, Muller YA, Hla T, Nielsen LB, Dahlback B (2011) Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci USA 108:9613–9618PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Indian Society of Haematology & Transfusion Medicine 2015

Authors and Affiliations

  • Weiying Gu
    • 1
  • Lili Xiang
    • 2
  • Tingxiu Jiang
    • 3
  • Guanghua Luo
    • 4
  • Jiang Wei
    • 4
  • Jiannong Cen
    • 5
  • Zixing Chen
    • 5
  • Guoqiang Qiu
    • 1
  • Mei Zeng
    • 1
  • Xiaoying Zhang
    • 4
    Email author
  1. 1.Department of Hematology, The First People’s Hospital of ChangzhouThird Affiliated to Suzhou UniversityChangzhouChina
  2. 2.Department of HematologyThe Center Hospital of XuzhouXuzhouChina
  3. 3.Department of HematologyThe Fourth Affiliated Hospital of Guangxi Medical UniversityLiuzhouChina
  4. 4.Comprehensive Laboratory, The First People’s Hospital of ChangzhouThird Affiliated to Suzhou UniversityChangzhouChina
  5. 5.Jiangsu Institute of HematologyThe First Affiliated Hospital of Suzhou UniversitySuzhouChina

Personalised recommendations